by Staff Writers
Paris (AFP) Aug 17, 2011
Researchers into HIV said they had identified 17 potent antibodies whose discovery opened up valuable pathways in the search for an AIDS vaccine.
Antibodies are the foot soldiers in the immune system, latching onto viral or microbial intruders and tagging them for destruction by specialised "killer" cells.
Priming antibodies to recognise pathogens is a textbook method in vaccines, although it has proven agonisingly hard in the case of the human immunodeficiency virus (HIV) which causes AIDS.
The new "broadly neutralising" antibodies are the biggest single haul so far and also many times more potent than those found previously, the scientists report in Thursday's issue of the British journal Nature.
"Most antiviral vaccines depend on stimulating the antibody response to work effectively," said Dennis Burton of the Scripps Research Institute in La Jolla, California.
"Because of HIVs remarkable variability, an effective HIV vaccine will probably have to elicit broadly neutralizing antibodies. This is why we expect that these new antibodies will prove to be valuable assets to the field of AIDS vaccine research."
The International AIDS Vaccine Initiative (IAVI), a US NGO that sponsored the search, said the quest for HIV-neutralising antibodies was "perhaps the greatest challenge" facing vaccine engineers.
The 17 antibodies were isolated from four individuals with HIV, an achievement similar to looking for a needle in a haystack as only a very small number of people produce these powerful molecules.
AIDS has claimed some 30 million lives since the disease came to public notice in 1981. Around 34 million people today are infected with HIV, according to UN estimates.
Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.
New drug could cure nearly any viral infection
Boston MA (SPX) Aug 12, 2011
Most bacterial infections can be treated with antibiotics such as penicillin, discovered decades ago. However, such drugs are useless against viral infections, including influenza, the common cold, and deadly hemorrhagic fevers such as Ebola. Now, in a development that could transform how viral infections are treated, a team of researchers at MIT's Lincoln Laboratory has designed a drug th ... read more
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2011 - Space Media Network. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement|